-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
CB Scientific, Inc. Announces Uplist to the OTCQB(R) Venture Market
CB Scientific, Inc. Announces Uplist to the OTCQB(R) Venture Market
Shareholders to benefit from greater transparency and improved liquidity
ESCONDIDO, CA / ACCESSWIRE / April 6, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announces its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). The Company will commence trading on the OTCQB with the market open on April 6, 2022, under the symbol "CBSC."
"Trading on OTCQB is an important achievement for our Company, providing increased transparency and improved liquidity to both existing and prospective shareholders," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "In combination with plans underway for ongoing corporate growth through the balance of the year, we believe listing on the OTCQB will allow our story to reach a wider investor audience, a key objective for the Company in 2022."
OTCQB is operated by OTC Markets Group, Inc. and is designed for early-stage and developing companies in the United States and abroad. To be eligible for OTCQB quotes, companies must be current in their disclosure filings, have audited financial statements, and undergo an annual validation and management certification process. Companies must also meet minimum bid testing and other financial terms. OTCQB is recognized as an established public market by the Securities and Exchange Commission ("SEC") and provides current public information to investors in need of securities analysis, valuation, and trading.
"Realizing this significant accomplishment represents another major milestone in the Company's pursuit of planned business objectives," said Paul Danner, Chairman of CB Scientific, Inc. "We are now positioned to move forward with our plans to implement a corporate name change which more accurately describes our business direction and future growth potential, and relocation of our corporate domicile to Nevada which provides superior tax laws and corporate regulations."
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About CB Scientific, Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View source version on accesswire.com:
Shareholders to benefit from greater transparency and improved liquidity
股東將受益於更高的透明度和更好的流動性
ESCONDIDO, CA / ACCESSWIRE / April 6, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announces its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market (the "OTCQB"). The Company will commence trading on the OTCQB with the market open on April 6, 2022, under the symbol "CBSC."
加利福尼亞州埃斯孔迪多/ACCESSWIRE/2022年4月6日/CB Science。無創動態心臟監護儀產品和服務的設計商、製造商和分銷商CBSC公司(以下簡稱“CBSC”或“公司”)今天宣佈,該公司成功地從場外交易粉單上升到場外交易®創業板市場(以下簡稱“OTCQB”)。該公司將於2022年4月6日在場外交易市場開始交易,交易代碼為“CBSC”。
"Trading on OTCQB is an important achievement for our Company, providing increased transparency and improved liquidity to both existing and prospective shareholders," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "In combination with plans underway for ongoing corporate growth through the balance of the year, we believe listing on the OTCQB will allow our story to reach a wider investor audience, a key objective for the Company in 2022."
CB Science公司首席執行官查爾斯·馬丁説:“在場外交易市場進行交易是我們公司的一項重要成就,為現有股東和潛在股東提供了更高的透明度和更好的流動性。”結合今年剩餘時間公司持續增長的計劃,我們相信在OTCQB上市將使我們的故事接觸到更廣泛的投資者受眾,這是公司2022年的關鍵目標。
OTCQB is operated by OTC Markets Group, Inc. and is designed for early-stage and developing companies in the United States and abroad. To be eligible for OTCQB quotes, companies must be current in their disclosure filings, have audited financial statements, and undergo an annual validation and management certification process. Companies must also meet minimum bid testing and other financial terms. OTCQB is recognized as an established public market by the Securities and Exchange Commission ("SEC") and provides current public information to investors in need of securities analysis, valuation, and trading.
OTCQB由OTC Markets Group,Inc.運營,專為美國和海外處於早期階段和發展中的公司而設計。要有資格獲得OTCQB報價,公司必須在其披露文件中保持最新,已審計財務報表,並經歷年度驗證和管理認證過程。公司還必須滿足最低投標測試和其他財務條款。場外交易市場被美國證券交易委員會(“美國證券交易委員會”)認可為成熟的公開市場,為需要進行證券分析、估值和交易的投資者提供最新的公開信息。
"Realizing this significant accomplishment represents another major milestone in the Company's pursuit of planned business objectives," said Paul Danner, Chairman of CB Scientific, Inc. "We are now positioned to move forward with our plans to implement a corporate name change which more accurately describes our business direction and future growth potential, and relocation of our corporate domicile to Nevada which provides superior tax laws and corporate regulations."
CB Science,Inc.董事長保羅·丹納説:“實現這一重大成就代表着公司追求計劃中的業務目標的又一個重要里程碑。我們現在準備推進我們的計劃,實施公司更名,更準確地描述我們的業務方向和未來的增長潛力,並將我們的公司註冊地遷往內華達州,這將提供更好的税法和公司法規。“
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
隨着更多新情況的出現,CB Science,Inc.計劃通過新聞稿和監管文件及時發佈公告,讓其股東、行業參與者和公開市場瞭解情況。
About CB Scientific, Inc.
關於CB Science,Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
CB Science,Inc.通過其國內和國際子公司,在動態非侵入性心臟監測領域提供創新的產品和服務。我們的FDA和CE批准的EKG設備、基於雲的交互式採集軟件和適用於iOS和Android平臺的智能手機應用程序為有異常心律風險的患者提供了更好的遵從性,併為醫生提供了更準確的信息。
Company Contact Information:
公司聯繫信息:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
電話:(888)225-0870
電子郵件:General Query:Info@cbScience ficinc.com
投資者諮詢:Robert Hesse-dorchco.bh@gmail.com
關注CBSC:Twitter、Facebook、Instagram、LinkedIn、YouTube和時事通訊
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
這一信息披露可能包含《1995年私人證券訴訟法案》所涵蓋的前瞻性陳述。這些前瞻性陳述涉及推出或增強我們的服務和產品的計劃和時間,有關未來市場狀況、供需狀況的陳述,以及本新聞稿中包含的其他預期、意圖和計劃,這些都不是歷史事實,涉及風險和不確定性。我們對未來收入的預期取決於我們開發和提供產品和服務的能力,這些產品和服務可能不是我們今天生產的,而且符合規定的規格。在本新聞稿中使用的“計劃”、“預期”、“相信”以及類似的表述通常代表前瞻性陳述。這些聲明反映了我們目前的預期。它們受到許多風險和不確定性的影響,包括但不限於技術的變化和普遍存在的市場的變化。本新聞稿包括1933年《證券法》第27A節和1934年《證券法》第27E節所指的前瞻性陳述。本新聞稿中包含的非歷史事實的陳述可能被視為前瞻性陳述。請投資者注意,前瞻性陳述本質上是不確定的。由於某些風險和不確定因素,包括但不限於獲得融資以及監管機構和股東對預期行動的批准的能力,實際業績和結果可能與本文預測或建議的情況大不相同。
SOURCE: CB Scientific, Inc.
資料來源:CB Science,Inc.
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧